Epigenetics in metabolic dysfunction-associated steatohepatitis

被引:0
|
作者
Zhang, Yanru [1 ,2 ]
Ding, Ruike [1 ,2 ]
Hu, Liangshuo [3 ]
Liu, Enqi [1 ,2 ]
Qu, Pengxiang [1 ,2 ]
机构
[1] Xi An Jiao Tong Univ, Lab Anim Ctr, Hlth Sci Ctr, Xian 710061, Peoples R China
[2] Minist Educ China, Key Lab Environm & Genes Related Dis, Xian 710049, Peoples R China
[3] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Xian, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
MASH; Epigenetics; Liver; DNA methylation; Histone modifications; Noncoding RNA; NONALCOHOLIC STEATOHEPATITIS; HEPATIC STEATOSIS; LIPID-METABOLISM; NONCODING RNAS; LIVER; EXPRESSION; DIET; HEPATOCYTES; FIBROSIS; INJURY;
D O I
10.1016/j.cellsig.2025.111684
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Metabolic dysfunction-associated steatohepatitis (MASH) is a complex disease involving genetics, environment, and lifestyle, with the potential to progress to liver fibrosis, cirrhosis, and even hepatocellular carcinoma (HCC). Although the pathogenesis of MASH is not fully clear, increasing evidence has indicated that epigenetics plays an important role in the genesis and progression of MASH, during which, as drastic changes in metabolites, epigenetics undergo drastic changes. Roles of chromatin structure, chromatin accessibility, DNA methylation, histone modification, and non-coding RNAs were considered as bridges of pathogenic factors and MASH. In this review, the research progress on the epigenetics of MASH was summarized, and indepth research and therapeutic strategies based on epigenetics is expected to bring new hope to MASH patients.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Current Progress and Challenges in the Development of Pharmacotherapy for Metabolic Dysfunction-Associated Steatohepatitis
    Zhi, Yang
    Dong, Yinuo
    Li, Xiaoyun
    Zhong, Wei
    Lei, Xiaohong
    Tang, Jieting
    Mao, Yimin
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2024, 40 (07)
  • [32] Performance of MAST, FAST, and MEFIB in predicting metabolic dysfunction-associated steatohepatitis
    Qi, Shi
    Wei, Xiaodie
    Zhao, Jinhan
    Wei, Xinhuan
    Guo, Haiqing
    Hu, Jingxian
    Wuyun, Qiqige
    Pan, Calvin Q.
    Zhang, Nengwei
    Zhang, Jing
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (08) : 1656 - 1662
  • [33] Resmetirom for metabolic dysfunction-associated steatohepatitis: targeting hepatic and cardiovascular disease
    Lurje, Isabella
    Tacke, Frank
    HEPATOBILIARY SURGERY AND NUTRITION, 2024, 13 (06) : 1034 - 1037
  • [34] Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis
    Cha, Jung Hoon
    Park, Na Ri
    Cho, Sung Woo
    Nam, Heechul
    Yang, Hyun
    Jung, Eun Sun
    Jang, Jeong Won
    Choi, Jong Young
    Yoon, Seung Kew
    Sung, Pil Soo
    Bae, Si Hyun
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [35] Alterations of valsartan pharmacokinetics in a rodent model of metabolic dysfunction-associated steatohepatitis
    Farrera, Dominique O.
    Alaaldin, Mina M.
    Lindberg, Paige
    Sample, Paxton A.
    Lenzen-Hammerel, Paige
    Lamadrid, Christopher S.
    Haymore, Ryan
    Wright, Stephen H.
    Cherrington, Nathan J.
    DRUG METABOLISM AND DISPOSITION, 2025, 53 (03)
  • [36] Tirzepatide for treatment of metabolic dysfunction-associated steatohepatitis: relationship between metabolic and histological responses
    Caussy, C.
    Hartman, M. L.
    Thomas, M. K.
    Mather, K. J.
    Tang, Y.
    Loomba, R.
    Sanyal, A. J.
    DIABETOLOGIA, 2024, 67 : S121 - S121
  • [37] Identification of serum metabolome signatures associated with hepatocellular carcinoma in metabolic dysfunction-associated steatohepatitis
    Komori, Atsumasa
    Matsumoto, Kosuke
    Kugiyama, Yuki
    Suehiro, Tomoyuki
    Motoyoshi, Yasuhide
    Saeki, Akira
    Nagaoka, Shinya
    Yamasaki, Kazumi
    Yatsuhashi, Hiroshi
    JOURNAL OF HEPATOLOGY, 2024, 80 : S542 - S542
  • [38] Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
    Sanyal, Arun J.
    Husain, Mansoor
    Diab, Crystel
    Mangla, Kamal Kant
    Shoeb, Ahsan
    Lingvay, Ildiko
    Tapper, Elliot B.
    AMERICAN HEART JOURNAL PLUS: CARDIOLOGY RESEARCH AND PRACTICE, 2024, 41
  • [39] Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
    Sandireddy, Reddemma
    Sakthivel, Suganya
    Gupta, Priyanka
    Behari, Jatin
    Tripathi, Madhulika
    Singh, Brijesh Kumar
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [40] Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis
    Yashaswini, Chittampalli N.
    Qin, Tianyue
    Bhattacharya, Dipankar
    Amor, Corina
    Lowe, Scott
    Lujambio, Amaia
    Wang, Shuang
    Friedman, Scott L.
    JOURNAL OF HEPATOLOGY, 2024, 81 (02)